Literature DB >> 26057328

Effect of the Regenerative Agent Poly(Carboxymethylglucose Sulfate) on Corneal Wound Healing After Corneal Cross-Linking for Keratoconus.

George D Kymionis1, Dimitrios A Liakopoulos, Michael A Grentzelos, Konstantinos I Tsoulnaras, Efstathios T Detorakis, Béatrice Cochener, Miltiadis K Tsilimbaris.   

Abstract

PURPOSE: To evaluate the effect of a regenerative agent (RGTA) [Cacicol20-poly(carboxymethyl glucose sulfate); OTR3, Paris, France] on corneal reepithelialization and pain after corneal cross-linking (CXL) for keratoconus.
METHODS: In this prospective comparative (contralateral) clinical study, patients with bilateral progressive keratoconus underwent CXL treatment. The corneal epithelium during CXL was removed using transepithelial phototherapeutic keratectomy (Cretan protocol). One eye of each patient was randomly instilled with an RGTA (Cacicol20) once a day (study group), whereas the fellow eye was instilled with artificial tears (control group). Patients were examined daily until complete reepithelialization. Postoperative examinations included slit-lamp biomicroscopy to assess the epithelial defect size and subjective evaluation of pain.
RESULTS: The study enrolled 18 patients (36 eyes). The mean epithelial defect size for study and control groups was 19.6 ± 4.2 mm versus 21.5 ± 2.8 mm, respectively, at day 1 (P = 0.019) and 6.4 ± 3.4 mm versus 7.9 ± 4.3 mm, respectively, at day 2 (P = 0.014). At day 3 postoperatively, 61.1% of study eyes were fully reepithelialized, compared with 11.1% of control eyes (P = 0.002).
CONCLUSIONS: RGTA (Cacicol20) instillation seems to result in faster corneal reepithelialization after CXL in this study. However, there was no significant effect in subjective pain/discomfort.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26057328     DOI: 10.1097/ICO.0000000000000484

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  8 in total

1.  Matrix regeneration agents improve wound healing in non-stressed human corneal epithelial cells.

Authors:  A Robciuc; R P J Arvola; M Jauhiainen; J M Holopainen
Journal:  Eye (Lond)       Date:  2017-12-22       Impact factor: 3.775

2.  Corneal matrix repair therapy with the regenerating agent in neurotrophic persistent epithelial defects.

Authors:  Canan Asli Utine; Ceren Engin Durmaz; Nilufer Koçak
Journal:  Int J Ophthalmol       Date:  2017-12-18       Impact factor: 1.779

3.  Evaluation of artificial tears on cornea epithelium healing.

Authors:  Ying Zhang; Xiao-You Lu; Ren-Jian Hu; Fang-Li Fan; Xiu-Ming Jin
Journal:  Int J Ophthalmol       Date:  2018-07-18       Impact factor: 1.779

Review 4.  RGTA® or ReGeneraTing Agents mimic heparan sulfate in regenerative medicine: from concept to curing patients.

Authors:  Denis Barritault; Marie Gilbert-Sirieix; Kim Lee Rice; Fernando Siñeriz; Dulce Papy-Garcia; Christophe Baudouin; Pascal Desgranges; Gilbert Zakine; Jean-Louis Saffar; Johan van Neck
Journal:  Glycoconj J       Date:  2016-12-07       Impact factor: 2.916

5.  Effect of Topically Administered Chitosan-N-acetylcysteine on Corneal Wound Healing in a Rabbit Model.

Authors:  Corinna Fischak; Robert Klaus; René M Werkmeister; Christine Hohenadl; Martin Prinz; Leopold Schmetterer; Gerhard Garhöfer
Journal:  J Ophthalmol       Date:  2017-06-12       Impact factor: 1.909

Review 6.  Application of Novel Drugs for Corneal Cell Regeneration.

Authors:  Sang Beom Han; Yu-Chi Liu; Karim Mohamed-Noriega; Jodhbir S Mehta
Journal:  J Ophthalmol       Date:  2018-05-02       Impact factor: 1.909

7.  Case Reports for Topical Treatment of Corneal Ulcers with a New Matrix Therapy Agent or RGTA® in Dogs.

Authors:  Jessica A Martinez; Franck Chiappini; Denis Barritault
Journal:  Vet Sci       Date:  2019-12-13

Review 8.  Pain mechanisms and management in corneal cross-linking: a review.

Authors:  Emilie Sophie van der Valk Bouman; Heather Pump; David Borsook; Boris Severinsky; Robert Pl Wisse; Hajirah N Saeed; Eric A Moulton
Journal:  BMJ Open Ophthalmol       Date:  2021-11-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.